XML 32 R21.htm IDEA: XBRL DOCUMENT v3.21.2
Collaboration Agreements, In-Licensing Arrangements And Business Development Activities (Tables)
 9 Months Ended
Oct. 01, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Collaborative Revenues Under Collaboration Agreement
Revenues under the collaboration agreement with Ipsen were as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2021202020212020
License revenues$25,139 $19,910 $81,246 $71,456 
Collaboration services revenues12,956 16,096 81,576 46,503 
Total$38,095 $36,006 $162,822 $117,959 
Revenues under the collaboration agreement with Takeda were as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2021202020212020
License revenues$20,078 $9,780 $23,476 $32,726 
Collaboration services revenues2,656 13,204 10,815 16,468 
Total$22,734 $22,984 $34,291 $49,194 
License revenues under the collaboration agreement with Genentech were as follows (in thousands):
 Three Months Ended September 30,Nine Months Ended September 30,
 2021202020212020
Profits on U.S. commercialization$1,743 $1,595 $5,697 $4,378 
Royalty revenues on ex-U.S. sales$1,576 $1,370 $3,309 $3,804